There were no significant news releases or other significant events that could be detected.
Provectus develops therapies designed to target and destroy breast cancer, liver cancer, and metastatic melanoma while eliminating side effects.
The company has a tiny market cap of only $86 million. It has $7 million in cash and about $360,000 in debt according to the latest Yahoo! financial data. The company has not registered any significant revenues from operations over the last couple of years.
Shares of Provectus closed at $1.90 on Monday, 12% below the 52-week high of $2.16.
Provectus has made BHI's BioWatch Alert List, and will be tracked for the next two weeks.